Magnetic resonance imaging contrast media in the subarachnoid space: A comparison between gadodiamide injection and gadopentetate dimeglumine in an experimental study in pigs

Investigative Radiology

Volumn 32, Issue 3, 1997, Pages 140-148

  Skalpe, Ingar Ole ^a,b   Tang, Guang Jian ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

cerebrospinal fluid; cisternography; contrast media; gadolinium chelates; Magnetic resonance

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; IONIC CONTRAST MEDIUM; NONIONIC CONTRAST MEDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; INTRASPINAL DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; PRIORITY JOURNAL; SUBARACHNOID SPACE; SWINE;

EID: 0343118117     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199703000-00002     Document Type: Article

References (20)

1. Brant-Zawadzki MN, Berry I, Osaki L, et al. Gd-DTPA in clinical MR of the brain. 1: Intraaxial lesions. AJNR Am J Neuroradiol 1986;7:781-788.
2. Brant-Zawadzki MN, Berry I, Osaki L, et al. Gd-DTPA in clinical MR of the brain. 2: Extraaxial lesions and normal structures. AJNR Am J Neuroradiol 1986;7:789-783.
3. Niendorf HP, Tolerance and safety of Gd-DTPA in 7000 patients. Diagn Imaging 1988;6:S16-S17.
4. Goldstein HA, Kashanian FK, Blumetti RS, et al. Safety assessment of gadopentetate dimeglumine in US clinical trials. Radiology 1990;174:17-23.
5. Runge VM, Bradley WG, Brant-Zawadzki MN, et al. Clinical safety and efficacy of gadoteridol: A study in 411 patients with suspected intracranial and spinal disease. Radiology 1991;181:701-709.
6. Ball WS, Nadel SN, Zimmerman, RA, et al. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 1993;186:769-774.
7. Di Chiro G, Knop RH, Girton ME, et al. MR cisternography and myelography with Gd-DTPA in monkeys. Radiology 1985;157:373-377.
8. Di Chiro G, Girton ME, Frank JA, et al. Cerebrospinal fluid rhinorrhea: Depiction with MR cisternography in dogs. Radiology 1986;160:221-222.
9. Weinmann HJ, Press WR, Gries H. Tolerance of extracellular contrast agents for magnetic resonance imaging. Invest Radiol 1990;25:S49-S50.
10. Brasch RC, Weinmann HJ, Wesbey GE, Contrast-enhanced NMR. Imaging: Animal studies using gadolinium-DTPA complex. AJR Am J Roentgenol 1984;142:625-630.
11. Skalpe IO, Lumbar myelography with Conray Meglumin 282: Report of 100 investigations with special reference to the adverse effects. Acta Neurol Scandinav 1971;47:569-578.
12. Skalpe IO, Gjone R. Bladder function during lumbar myelography: An experimental investigation in cats. Acta Radiol 1972; 335(suppl):175-185.
13. Skalpe IO, Tang G. Animal experimental myelography in the pig: A comparison between iohexol and iotrolan. Invest Radiol 1995;30:239-243.
14. Amundsen P, Skalpe IO. Cervical myelography with a water-soluble contrast medium (metrizamide). Neuroradiology 1975;8:209-212.
15. Schumann-Gampieri G, Schmitt WH, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in the MR imaging of the hepatobiliary system. Radiology 1992;183:59.
16. Arnell S, Lidstrøm F. Myelography with skiodan (Abrodil). Acta Radiol 1931;12:287-288.
17. Guyton AC, Hall JE, Textbook of medical physiology. Philadelphia, PA: WB Saunders Co., 1994.
18. Skalpe IO, Torbergsen T, Amundsen P, Presthus J. Lumbar myelography with metrizamide. Acta Radiol 1973;335(suppl):367-379.
19. Normann PT, Hals PA. In vivo stability and excretion of gadodiamide (Gd-DTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging. Eur J Drug Pharmakokinet 1995;20:307-313.
20. Okazaki O, Kurata T, Yoshioka N, Hakusui H. Pharmakokinetics and stability of caldiamide sodium in rats. Arzneim-Forsch/Drug Res 1996;46:79-83.